Latest news and press releases about Protagonist Therapeutics, Inc. (PTGX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders.
Price
| Price | $142.84 |
| Market Cap | $9.2B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 8.71 |
| EV / EBITDA | -42.43 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -21.17% |
| Return on Invested Capital | -25.23% |
| Return on Assets | -19.43% |
| Gross Margin | 97.34% |
| Operating Margin | -343.63% |
| Net Margin | -282.83% |
Related companies: ACLX · AKRO · ALKS · CRNX · IMVT · KYMR · NAMS
Explore sector: Healthcare · Biotechnology
More sections of PTGX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks